Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
12.13
+0.37 (3.10%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Bicara Therapeutics Analyst Ratings
Total Analysts
7
Consensus Rating
Buy
Price Target
$29.67
Upside
+144.70%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Sell Initiates $8 | Sell | Initiates | $8 | -34.02% | Apr 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +262.89% | Apr 7, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $13 | Buy | Reiterates | $13 | +7.30% | Mar 13, 2025 |
| Wedbush | Wedbush | Buy Reiterates $31 | Buy | Reiterates | $31 | +155.67% | Feb 12, 2025 |
| Wedbush | Wedbush | Buy Initiates $31 | Buy | Initiates | $31 | +155.67% | Feb 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +271.13% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +246.39% | Dec 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Oct 8, 2024 |
| Stifel | Stifel | Strong Buy Initiates $47 | Strong Buy | Initiates | $47 | +287.63% | Oct 8, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $35 | Buy | Initiates | $35 | +188.66% | Oct 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Oct 8, 2024 |